Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: A cost-effectiveness analysis

Journal of Infectious Diseases

Volumn 214, Issue 5, 2016, Pages 685-688

  Laprise, Jean François ^a   Markowitz, Lauri E ^b   Chesson, Harrell W ^b   Drolet, Mélanie ^a   Brisson, Marc ^a,c,d  

^a University Laval   (Canada)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cost effectiveness; HPV vaccination; Human papillomavirus (HPV); Transmission dynamic modeling

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; HEALTH CARE COST; HEALTH IMPACT ASSESSMENT; HUMAN; INCIDENCE; INFECTION PREVENTION; MEDICAL CARE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SCREENING; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS; COMPARATIVE STUDY; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES;

EID: 84988938016     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw227     Document Type: Article

References (15)

1. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16:775-86.
2. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802.
3. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother 2016; 12:20-9.
4. WorldHealthOrganization (WHO). Evidence based recommendations on human papilloma virus (HPV) vaccines schedules: background paper for SAGE discussions. http://www.who.int/immunization/sage/meetings/2014/april/1-HPV-Evidence-based-recommendationsWHO-with-Appendices2-3.pdf. Accessed 23 July 2014.
5. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23.
6. Brisson M, Laprise JF, Chesson HW, et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst 2016; 108:djv282.
7. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices.MMWR Morb Mortal Wkly Rep 2015; 64:300-4
8. Luxembourg A. Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine. Presented at: Meeting of the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 24 February 2016. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-02/hpv-03-luxembourg.pdf.
9. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014; 63:620-4.
10. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:784-92.
11. Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015; 350:g7584.
12. Laprise JF, Drolet M, Boily MC, et al. Comparing the cost-effectiveness of twoand three-dose schedules of human papillomavirus vaccination: a transmissiondynamic modelling study. Vaccine 2014; 32:5845-53.
13. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014; 10:2147-62.
14. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 2014; 134:e657-65.
15. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121:829-46.